Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.
1. An immunogenic RNA bacteriophage virus-like particle (VLP) comprising an RNA bacteriophage single chain coat polypeptide dimer comprising (i) an upstream coat protein subunit, (ii) a downstream coat protein subunit, and (iii) a heterologous Respiratory Syncytial Virus (RSV) glycoprotein F peptide inserted in the downstream coat protein subunit, wherein the RSV glycoprotein F peptide consists of an amino acid sequence corresponding to 10 contiguous amino acids of SEQ ID NO:5, wherein the RNA bacteriophage VLP when introduced to a mammal induces production of an antibody that binds the RSV glycoprotein F peptide.
2. The RNA bacteriophage VLP of claim 1 , wherein the VLP is a PP7 or MS2 VLP.
3. The RNA bacteriophage VLP of claim 1 , wherein the RSV peptide consists of a peptide having the amino acids of SEQ ID NO:13.
4. The RNA bacteriophage of claim 1 , wherein the RSV peptide is inserted at the amino terminus of the downstream subunit.
5. The RNA bacteriophage of claim 1 , wherein the RSV peptide is inserted in the AB loop of the downstream subunit.